Dyax - Advancing Novel Biotherapeutics

Dedicated to finding new solutions for patients in need.

Home>Investors>SEC Filings

SEC Filings

Form 10-Q
DYAX CORP filed this Form 10-Q on May 3, 2010
Document Outline
Entire Document (1032 KB)
Subdocument 1 - 10-Q - Quarterly report pursuant to sections 13 or 15(d)
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - PART I – FINANCIAL INFORMATION
Page 4 - Dyax Corp. and Subsidiaries Consolidated Statements of Operations and Comprehensive Income (Loss) (U
Page 5 - Dyax Corp. and Subsidiaries Consolidated Statements of Cash Flows (Unaudited)
Page 6 - 1. BUSINESS OVERVIEW
Page 7 - Basis of Consolidation
Page 8 - Inventories
Page 9 - Product Sales Allowances
Page 10 - Development and License Fee Revenue
Page 11 - Patent Licenses
Page 12 - Translation of Foreign Currencies
Page 13 - Business Segments
Page 14 - Description (in millions)
Page 15 - N/A
Page 16 - 7. STOCKHOLDER’S EQUITY (DEFICIT) AND STOCK-BASED COMPENSATION
Page 17 - Three Months Ended
Page 18 - 10. INCOME TAXES
Page 19 - N/A
Page 20 - Sales and Marketing
Page 21 - KALBITOR Outside of the United States
Page 22 - DX-88 for Ophthalmic Indications.
Page 23 - Research and Development
Page 24 - Liquidity and Capital Resources
Page 25 - Financing Activities
Page 26 - Product Sales
Page 27 - N/A
Page 28 - Changes in Internal Control over Financial Reporting
Page 29 - We may need substantial additional capital in the future and may be unable to raise the capital that
Page 30 - Our revenues and operating results have fluctuated significantly in the past, and we expect this to
Page 31 - Because the target patient population of KALBITOR for treatment of HAE is small and has not been def
Page 32 - N/A
Page 33 - N/A
Page 34 - If we are unable to establish and maintain effective sales, marketing and distribution capabilities,
Page 35 - N/A
Page 36 - We rely on third-party manufacturers to produce our preclinical and clinical drug supplies and we in
Page 37 - Our biopharmaceutical product candidates must undergo rigorous clinical trials which could substanti
Page 38 - We lack experience in and/or capacity for conducting clinical trials and handling regulatory process
Page 39 - Product liability and other claims arising in connection with the testing our product candidates in
Page 40 - N/A
Page 41 - If we fail to establish and maintain strategic license, research and collaborative relationships, or
Page 42 - N/A
Page 43 - Proceedings to obtain, enforce or defend patents and to defend against charges of infringement are t
Page 44 - If we lose or are unable to hire and retain qualified personnel, then we may not be able to develop
Page 45 - Compliance with changing regulations relating to corporate governance and public disclosure may resu
Page 46 - N/A
Page 47 - EXHIBIT
Page 48 - N/A
Page 49 - EXHIBIT NO.
Subdocument 2 - EX-31.1 -
Page 1 - N/A
Subdocument 3 - EX-31.2 -
Page 1 - N/A
Subdocument 4 - EX-32 -
Page 1 - N/A

Stock quote

ExchangeNASDAQ (US Dollar)
Price$2.51
Change (%) Stock is Up 0.09 (3.72%)
See more

IR Tool Kit

E-mail Alerts  E-mail Alerts
IR Contacts  IR Contacts
RSS Feeds  RSS Feeds
Investor Kit  Online Investor Kit

Investor Relations Contacts

Ivana Magovcevic-Liebisch
Executive Vice President Corporate Development and General Counsel
Dyax Corp.
Phone: 617-225-2500


Nicole Jones
Director, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500


JENNIFER VIERA
Manager, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500

See All